| Arcus Biosciences [RCUS] - Last Close: $18.81 Arcus Biosciences is getting a boost in today's premarket. The biotech stock is gaining after Swiss rival Roche [RHHBY] inadvertently published positive interim data from trials of its lung cancer drug. Roche Group subsidiary Genentech shared data from a Phase III SKYSCRAPER-01 study evaluating tiragolumab plus Tecentriq®. The clinical update provoked an uptick in Arcus Bio, who is developing a similar treatment. RCUS is up 34.5% in the premarket. My Take: It was hard to pin down the catalyst for this rally, but this looks like it. RCUS could see gains if its drug performs similarly. Apellis Pharma [APLS] - Last Close: $30.76 An upbeat clinical update is rallying shares of Apelis Pharma. The pharma firm said an ongoing review of syfovre showed no signs of an increased risk of retinal vasculitis associated with an increased risk of vision loss. Apellis said phase 3 investigators confirmed there were zero instances of retinal vasculitis observed during the trial. "As part of our ongoing review, we have seen no indication that drug product or manufacturing issues contributed to these events," said CEO Cedric Francois. APLS is up 25.9% in response to the clinical update. My Take: APLS seems to have convinced the market that this treatment is mostly safe, but it still has a steep hill to climb before it gets back to its 52-week highs. Iteos Therapeutics [ITOS] - Last Close: $11.75 A rebound rally is boosting shares of Iteos Therapeutics. The micro-cap biotech stock set a new 52-week low yesterday after an analyst downgrade earlier this week. However, shares are rebounding dramatically in today's premarket trading session. ITOS is up 37.0% in early premarket trading. My Take: ITOS may have bottomed out, but I want to see more progress before I'm sold. Heliogen [HLGN] - Last Close: $0.211 Heliogen is running hot after an upbeat regulatory decision. The company said the U.S. Patent & Trademark Office awarded it a new patent titled "gas receiver for capturing solar energy." Heliogen unveiled the patent late Tuesday, and shares gained 5.5% following the announcement. The rally continued into the after-market, and Heliogen is still running hot this morning. HLGN is up 34.3% in today's premarket. My Take: HLGN has had a rough run lately, but it has strong support at $0.21 and this catalyst could help it rebound into a new trading range. GainersBioNexus Gene Lab [BGLC] >> +29.7%CF Acquisiton [CFFEU] >> +30.7%Rail Vision Unit [RVSN] >> +25.0%LAMF Global Ventures [LGVC] >> +21.1%DeclinersFoot Locker [FL] >> (30.6%) Peloton Interactive [PTON] >> (28.4%)VinFast Auto [VFS] >> (15.6%)AMC Entertainment [AMC] >> (19.2%) Analog Devices, Inc. [ADI] ... AM
Grab Holdings Limited [GRAB] ... AM
Bath & Body Works, Inc. [BBWI] ... AM
Williams-Sonoma, Inc. [WSM] ... AM
Full Truck Alliance Co. Ltd. Dr [YMM] ... AM
Nvidia Corporation [NVDA] ... PM
Snowflake Inc. [SNOW] ... PM
Autodesk, Inc. [ADSK] ... PM
Splunk Inc. [SPLK] ... PM
Netapp, Inc. [NTAP] ... PM S&P flash U.S. services PMI [Aug] ... 9:45aS&P flash U.S. manufacturing PMI [Aug] ... 9:45a New home sales [Jul] ... 10:00a | 